Management of recurrent viral hepatitis B and C after liver transplantation.
Liver transplant teams are often faced with the challenges of managing viral recurrence after liver transplantation. Hepatitis C virus (HCV) remains the most challenging viral disease in the transplant community. Strategies to prevent and delay viral recurrence have slowly developed over the past 5 years. Hepatitis B virus (HBV), previously a contraindication for liver transplantation due to recurrence and cholestasis with allograft failure, is now one of the more favorable indications for liver transplantation as a result of current therapeutic options. This review investigates the up-to-date information on treatment outcomes for HCV and HBV in the period following liver transplant.
Montalbano
Marzia
M
University of Cincinnati, 231 Albert Sabin Way, MSB Room 6560, Cincinnati, OH 45267-0595, USA.
Neff
Guy W
GW
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D006509:Hepatitis B / Q000601:surgery* / Q000821:virology; D006526:Hepatitis C / Q000601:surgery* / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D018579:Patient Selection; D011183:Postoperative Complications / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000998:Antiviral Agents; D007166:Immunosuppressive Agents